Difference between revisions
alzheimers
Source +0 −0
… 23 unchanged lines
Revision 185 as rendered
The amyloid hypothesis dominated for decades and drew hundreds of failed trials. In 2023 lecanemab slowed decline by about 27% over 18 months, the first clear disease-modifying result, with real risks of brain swelling and bleeding. Halting the disease, rather than slowing it, has not been achieved.
Posed 1906, Alois Alzheimer.
What would settle it
A trial endpoint: halted cognitive decline